ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance

ADMA BIOLOGICS, INC.

2023-FY EPS reported -$0.13 revenue$258,215,000

Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.
Q4 adjusted net income $8.5M (vs loss $12.2M); FY adjusted net income $0.7M (vs loss $59.2M).
FY 2024 guidance raised: revenue >$330M, net income >$65M, adjusted EBITDA >$90M.
FY 2025 guidance raised: revenue >$380M, net income >$115M, adjusted EBITDA >$140M.
Pipeline: S. pneumonia hyperimmune globulin potential peak rev $300-500M; ASCENIV pediatric study ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported the full year 2023 and the three months ended December 31, 2023 results: revenue Total revenues were $73.9 million for the quarter ended December 31, 2023. Guidance raised.

Period: the full year 2023 and the three months ended December 31, 2023
Revenue: Total revenues were $73.9 million for the quarter ended December 31, 2023
Guidance: raised
Result: preliminary results

Exact text from the filing

ADMA Biologics, Inc. issued a press release announcing its financial results for the full year 2023 and the three months ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-010088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.